Advaxis jumps after FDA grants orphan drug designation for ADXS-HPV

|About: Advaxis Inc. (ADXS)|By:, SA News Editor

Advaxis (ADXS +5.7%) shares jump after the FDA grants the company an orphan drug designation for its leading drug candidate, ADXS-HPV, which aims to treat HPV-caused head/neck cancer.